| HGNC Family | Cytochrome P450s (CYP) |
| Name | cytochrome P450, family 4, subfamily F, polypeptide 2 |
| Description | This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. The enzyme starts the process of inactivating and degrading leukotriene B4, a potent mediator of inflammation. This gene is part of a cluster of cytochrome P450 genes on chromosome 19. Another member of this family, CYP4F11, is approximately 16 kb away. [provided by RefSeq, Jul 2008] |
| Summary |
{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n Cytochrome P450 4F2 (CYP4F2) is emerging as a modest but important metabolic enzyme that influences both vitamin K and fatty acid metabolism, with consequent effects on warfarin anticoagulation, vitamin E status, vascular tone, and even stroke risk. A number of genome‐wide association and candidate gene studies have demonstrated that common polymorphisms in CYP4F2—most notably the nonsynonymous variant p.V433M (rs2108622)—reduce the enzyme’s ability to oxidize vitamin K1, thereby elevating hepatic vitamin K levels and leading to an increase in the warfarin dose required to achieve therapeutic anticoagulation (1,2,3,8,13,14,23). In addition, CYP4F2 is the only cytochrome P450 enzyme thus far shown to ω‐hydroxylate vitamin K1, a key step in its catabolism, and its activity toward other substrates (for example, tocopherols) helps explain differences in vitamin E half‐lives and bioactivity (5,22). CYP4F2 also participates in the metabolism of arachidonic acid to generate 20‐hydroxyeicosatetraenoic acid (20‐HETE), a vasoactive mediator that can influence blood pressure regulation and ischemic stroke risk; indeed, carriers of functional variants have been reported to exhibit alterations in 20‐HETE production and modestly higher systolic blood pressure, with some studies linking the gene variant to an increased risk of stroke in certain populations (6,11,18,21). Moreover, incorporation of CYP4F2 genotype data into warfarin or acenocoumarol dosing algorithms has been shown to improve dose prediction across diverse cohorts—including Asian, European, African‐American, and Hispanic populations—even though the effect size is relatively small compared with that of VKORC1 or CYP2C9 (1,2,7,9,10,14,15,16,17,19,20,23). Collectively, these findings support the notion that CYP4F2 plays a dual role in modulating the availability of vitamin K for coagulation and in generating lipid mediators that regulate vascular function, thereby contributing to interindividual variability in drug response and cardiovascular risk.\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n (1)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ", \n (2)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": ", \n (3)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": ", \n (4)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": ", \n (5)."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "5"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n (6)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "6"}]}, {"type": "t", "text": ", \n (7)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "7"}]}, {"type": "t", "text": ", \n (8)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "8"}]}, {"type": "t", "text": ", \n (9)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "9"}]}, {"type": "t", "text": ", \n (10)."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "10"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n (11)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "11"}]}, {"type": "t", "text": ", \n (12)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "12"}]}, {"type": "t", "text": ", \n (13)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "13"}]}, {"type": "t", "text": ", \n (14)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "14"}]}, {"type": "t", "text": ", \n (15)."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "15"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n (16)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "16"}]}, {"type": "t", "text": ", \n (17)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "17"}]}, {"type": "t", "text": ", \n (18)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "18"}]}, {"type": "t", "text": ", \n (19)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "19"}]}, {"type": "t", "text": ", \n (20)."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "20"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n (21)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "21"}]}, {"type": "t", "text": ", \n (22)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "22"}]}, {"type": "t", "text": ", \n (23)."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "23"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "PLoS Genet (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1371/journal.pgen.1000433"}], "href": "https://doi.org/10.1371/journal.pgen.1000433"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19300499"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19300499"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Michael D Caldwell, Tarif Awad, Julie A Johnson, et al. "}, {"type": "b", "children": [{"type": "t", "text": "CYP4F2 genetic variant alters required warfarin dose."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2007-11-122010"}], "href": "https://doi.org/10.1182/blood-2007-11-122010"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18250228"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18250228"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Matthew G McDonald, Mark J Rieder, Mariko Nakano, et al. "}, {"type": "b", "children": [{"type": "t", "text": "CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Pharmacol (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1124/mol.109.054833"}], "href": "https://doi.org/10.1124/mol.109.054833"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19297519"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19297519"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Stuart A Scott, Rame Khasawneh, Inga Peter, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenomics (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2217/pgs.10.49"}], "href": "https://doi.org/10.2217/pgs.10.49"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20504253"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20504253"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Timothy J Sontag, Robert S Parker "}, {"type": "b", "children": [{"type": "t", "text": "Influence of major structural features of tocopherols and tocotrienols on their omega-oxidation by tocopherol-omega-hydroxylase."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Lipid Res (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1194/jlr.M600514-JLR200"}], "href": "https://doi.org/10.1194/jlr.M600514-JLR200"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17284776"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17284776"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Natalie C Ward, I-Jung Tsai, Anne Barden, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hypertension (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1161/HYPERTENSIONAHA.107.104463"}], "href": "https://doi.org/10.1161/HYPERTENSIONAHA.107.104463"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18391101"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18391101"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Martina Teichert, Mark Eijgelsheim, Fernando Rivadeneira, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A genome-wide association study of acenocoumarol maintenance dosage."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hum Mol Genet (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/hmg/ddp309"}], "href": "https://doi.org/10.1093/hmg/ddp309"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19578179"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19578179"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Paola Borgiani, Cinzia Ciccacci, Vittorio Forte, et al. "}, {"type": "b", "children": [{"type": "t", "text": "CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenomics (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2217/14622416.10.2.261"}], "href": "https://doi.org/10.2217/14622416.10.2.261"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19207028"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19207028"}]}, {"type": "r", "ref": 9, "children": [{"type": "t", "text": "Pei-Chieng Cha, Taisei Mushiroda, Atsushi Takahashi, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hum Mol Genet (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/hmg/ddq389"}], "href": "https://doi.org/10.1093/hmg/ddq389"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20833655"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20833655"}]}, {"type": "r", "ref": 10, "children": [{"type": "t", "text": "E Pautas, C Moreau, I Gouin-Thibault, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/clpt.2009.178"}], "href": "https://doi.org/10.1038/clpt.2009.178"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19794411"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19794411"}]}, {"type": "r", "ref": 11, "children": [{"type": "t", "text": "Cristiano Fava, Martina Montagnana, Peter Almgren, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hypertension (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1161/HYPERTENSIONAHA.108.114199"}], "href": "https://doi.org/10.1161/HYPERTENSIONAHA.108.114199"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18574070"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18574070"}]}, {"type": "r", "ref": 12, "children": [{"type": "t", "text": "Maude Fer, Laurent Corcos, Yvonne Dréano, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Lipid Res (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1194/jlr.M800199-JLR200"}], "href": "https://doi.org/10.1194/jlr.M800199-JLR200"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18577768"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18577768"}]}, {"type": "r", "ref": 13, "children": [{"type": "t", "text": "Virginia Pérez-Andreu, Vanessa Roldán, Ana Isabel Antón, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2008-09-176222"}], "href": "https://doi.org/10.1182/blood-2008-09-176222"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19270263"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19270263"}]}, {"type": "r", "ref": 14, "children": [{"type": "t", "text": "Han-Jing Cen, Wu-Tao Zeng, Xiu-Yu Leng, et al. "}, {"type": "b", "children": [{"type": "t", "text": "CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Br J Clin Pharmacol (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1111/j.1365-2125.2010.03698.x"}], "href": "https://doi.org/10.1111/j.1365-2125.2010.03698.x"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20653676"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20653676"}]}, {"type": "r", "ref": 15, "children": [{"type": "t", "text": "Kendra A Ross, Abbigail W Bigham, Melissa Edwards, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Hum Genet (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/jhg.2010.73"}], "href": "https://doi.org/10.1038/jhg.2010.73"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20555338"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20555338"}]}, {"type": "r", "ref": 16, "children": [{"type": "t", "text": "Adam Bress, Shitalben R Patel, Minoli A Perera, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenomics (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2217/pgs.12.164"}], "href": "https://doi.org/10.2217/pgs.12.164"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "23215885"}], "href": "https://pubmed.ncbi.nlm.nih.gov/23215885"}]}, {"type": "r", "ref": 17, "children": [{"type": "t", "text": "Ruijuan Liang, Lei Li, Cuilan Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Thromb Thrombolysis (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s11239-012-0725-7"}], "href": "https://doi.org/10.1007/s11239-012-0725-7"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22528326"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22528326"}]}, {"type": "r", "ref": 18, "children": [{"type": "t", "text": "Shumin Deng, Gang Zhu, Fang Liu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Prog Neuropsychopharmacol Biol Psychiatry (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.pnpbp.2010.03.009"}], "href": "https://doi.org/10.1016/j.pnpbp.2010.03.009"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20227456"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20227456"}]}, {"type": "r", "ref": 19, "children": [{"type": "t", "text": "P S Wells, H Majeed, S Kassem, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Thromb Res (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.thromres.2009.11.020"}], "href": "https://doi.org/10.1016/j.thromres.2009.11.020"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20421126"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20421126"}]}, {"type": "r", "ref": 20, "children": [{"type": "t", "text": "Meng Wei, Fei Ye, Dujiang Xie, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Thromb Haemost (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1160/TH11-12-0848"}], "href": "https://doi.org/10.1160/TH11-12-0848"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22534826"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22534826"}]}, {"type": "r", "ref": 21, "children": [{"type": "t", "text": "Hu Ding, Guanglin Cui, Lan Zhang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenet Genomics (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/FPC.0b013e328336eefe"}], "href": "https://doi.org/10.1097/FPC.0b013e328336eefe"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20130494"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20130494"}]}, {"type": "r", "ref": 22, "children": [{"type": "t", "text": "Sabrina A Bardowell, David E Stec, Robert S Parker "}, {"type": "b", "children": [{"type": "t", "text": "Common variants of cytochrome P450 4F2 exhibit altered vitamin E-{omega}-hydroxylase specific activity."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Nutr (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3945/jn.110.128579"}], "href": "https://doi.org/10.3945/jn.110.128579"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20861217"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20861217"}]}, {"type": "r", "ref": 23, "children": [{"type": "t", "text": "Onkar Singh, Edwin Sandanaraj, Koilan Subramanian, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Drug Metab Pharmacokinet (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2133/dmpk.dmpk-10-rg-080"}], "href": "https://doi.org/10.2133/dmpk.dmpk-10-rg-080"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21084764"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21084764"}]}]}]}
|
| Synonyms | CPF2 |
| Proteins | CP4F2_HUMAN |
| NCBI Gene ID | 8529 |
| API | |
| Download Associations | |
| Predicted Functions |
 |
| Co-expressed Genes |
|
| Expression in Tissues and Cell Lines |
|
CYP4F2 has 4,108 functional associations with biological entities spanning 9 categories (molecular profile, organism, chemical, disease, phenotype or trait, functional term, phrase or reference, structural feature, cell line, cell type or tissue, gene, protein or microRNA, sequence feature) extracted from 109 datasets.
Click the + buttons to view associations for CYP4F2 from the datasets below.
If available, associations are ranked by standardized value
| Dataset | Summary | |
|---|---|---|
| Allen Brain Atlas Adult Human Brain Tissue Gene Expression Profiles | tissues with high or low expression of CYP4F2 gene relative to other tissues from the Allen Brain Atlas Adult Human Brain Tissue Gene Expression Profiles dataset. | |
| Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles | tissues with high or low expression of CYP4F2 gene relative to other tissues from the Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles dataset. | |
| Allen Brain Atlas Aging Dementia and Traumatic Brain Injury Tissue Sample Gene Expression Profiles | tissue samples with high or low expression of CYP4F2 gene relative to other tissue samples from the Allen Brain Atlas Aging Dementia and Traumatic Brain Injury Tissue Sample Gene Expression Profiles dataset. | |
| Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by Microarray | tissue samples with high or low expression of CYP4F2 gene relative to other tissue samples from the Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by Microarray dataset. | |
| Allen Brain Atlas Prenatal Human Brain Tissue Gene Expression Profiles | tissues with high or low expression of CYP4F2 gene relative to other tissues from the Allen Brain Atlas Prenatal Human Brain Tissue Gene Expression Profiles dataset. | |
| BioGPS Cell Line Gene Expression Profiles | cell lines with high or low expression of CYP4F2 gene relative to other cell lines from the BioGPS Cell Line Gene Expression Profiles dataset. | |
| BioGPS Human Cell Type and Tissue Gene Expression Profiles | cell types and tissues with high or low expression of CYP4F2 gene relative to other cell types and tissues from the BioGPS Human Cell Type and Tissue Gene Expression Profiles dataset. | |
| BioGPS Mouse Cell Type and Tissue Gene Expression Profiles | cell types and tissues with high or low expression of CYP4F2 gene relative to other cell types and tissues from the BioGPS Mouse Cell Type and Tissue Gene Expression Profiles dataset. | |
| Carcinogenome Chemical Perturbation Carcinogenicity Signatures | small molecule perturbations changing expression of CYP4F2 gene from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset. | |
| CCLE Cell Line Gene CNV Profiles | cell lines with high or low copy number of CYP4F2 gene relative to other cell lines from the CCLE Cell Line Gene CNV Profiles dataset. | |
| CCLE Cell Line Gene Expression Profiles | cell lines with high or low expression of CYP4F2 gene relative to other cell lines from the CCLE Cell Line Gene Expression Profiles dataset. | |
| ChEA Transcription Factor Binding Site Profiles | transcription factor binding site profiles with transcription factor binding evidence at the promoter of CYP4F2 gene from the CHEA Transcription Factor Binding Site Profiles dataset. | |
| ChEA Transcription Factor Targets | transcription factors binding the promoter of CYP4F2 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets dataset. | |
| ChEA Transcription Factor Targets 2022 | transcription factors binding the promoter of CYP4F2 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets 2022 dataset. | |
| ClinVar Gene-Phenotype Associations 2025 | phenotypes associated with CYP4F2 gene from the curated ClinVar Gene-Phenotype Associations 2025 dataset. | |
| CMAP Signatures of Differentially Expressed Genes for Small Molecules | small molecule perturbations changing expression of CYP4F2 gene from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset. | |
| COMPARTMENTS Curated Protein Localization Evidence Scores | cellular components containing CYP4F2 protein from the COMPARTMENTS Curated Protein Localization Evidence Scores dataset. | |
| COMPARTMENTS Curated Protein Localization Evidence Scores 2025 | cellular components containing CYP4F2 protein from the COMPARTMENTS Curated Protein Localization Evidence Scores 2025 dataset. | |
| COMPARTMENTS Experimental Protein Localization Evidence Scores 2025 | cellular components containing CYP4F2 protein in low- or high-throughput protein localization assays from the COMPARTMENTS Experimental Protein Localization Evidence Scores 2025 dataset. | |
| COMPARTMENTS Text-mining Protein Localization Evidence Scores | cellular components co-occuring with CYP4F2 protein in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores dataset. | |
| COMPARTMENTS Text-mining Protein Localization Evidence Scores 2025 | cellular components co-occuring with CYP4F2 protein in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores 2025 dataset. | |
| COSMIC Cell Line Gene CNV Profiles | cell lines with high or low copy number of CYP4F2 gene relative to other cell lines from the COSMIC Cell Line Gene CNV Profiles dataset. | |
| COSMIC Cell Line Gene Mutation Profiles | cell lines with CYP4F2 gene mutations from the COSMIC Cell Line Gene Mutation Profiles dataset. | |
| CTD Gene-Chemical Interactions | chemicals interacting with CYP4F2 gene/protein from the curated CTD Gene-Chemical Interactions dataset. | |
| CTD Gene-Disease Associations | diseases associated with CYP4F2 gene/protein from the curated CTD Gene-Disease Associations dataset. | |
| dbGAP Gene-Trait Associations | traits associated with CYP4F2 gene in GWAS and other genetic association datasets from the dbGAP Gene-Trait Associations dataset. | |
| DepMap CRISPR Gene Dependency | cell lines with fitness changed by CYP4F2 gene knockdown relative to other cell lines from the DepMap CRISPR Gene Dependency dataset. | |
| DISEASES Curated Gene-Disease Association Evidence Scores 2025 | diseases involving CYP4F2 gene from the DISEASES Curated Gene-Disease Association Evidence Scores 2025 dataset. | |
| DISEASES Text-mining Gene-Disease Association Evidence Scores | diseases co-occuring with CYP4F2 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores dataset. | |
| DISEASES Text-mining Gene-Disease Association Evidence Scores 2025 | diseases co-occuring with CYP4F2 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores 2025 dataset. | |
| DisGeNET Gene-Disease Associations | diseases associated with CYP4F2 gene in GWAS and other genetic association datasets from the DisGeNET Gene-Disease Associations dataset. | |
| DisGeNET Gene-Phenotype Associations | phenotypes associated with CYP4F2 gene in GWAS and other genetic association datasets from the DisGeNET Gene-Phenoptype Associations dataset. | |
| DrugBank Drug Targets | interacting drugs for CYP4F2 protein from the curated DrugBank Drug Targets dataset. | |
| ENCODE Histone Modification Site Profiles | histone modification site profiles with high histone modification abundance at CYP4F2 gene from the ENCODE Histone Modification Site Profiles dataset. | |
| ENCODE Transcription Factor Binding Site Profiles | transcription factor binding site profiles with transcription factor binding evidence at the promoter of CYP4F2 gene from the ENCODE Transcription Factor Binding Site Profiles dataset. | |
| ENCODE Transcription Factor Targets | transcription factors binding the promoter of CYP4F2 gene in ChIP-seq datasets from the ENCODE Transcription Factor Targets dataset. | |
| GAD Gene-Disease Associations | diseases associated with CYP4F2 gene in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset. | |
| GAD High Level Gene-Disease Associations | diseases associated with CYP4F2 gene in GWAS and other genetic association datasets from the GAD High Level Gene-Disease Associations dataset. | |
| GDSC Cell Line Gene Expression Profiles | cell lines with high or low expression of CYP4F2 gene relative to other cell lines from the GDSC Cell Line Gene Expression Profiles dataset. | |
| GeneRIF Biological Term Annotations | biological terms co-occuring with CYP4F2 gene in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset. | |
| GeneSigDB Published Gene Signatures | PubMedIDs of publications reporting gene signatures containing CYP4F2 from the GeneSigDB Published Gene Signatures dataset. | |
| GEO Signatures of Differentially Expressed Genes for Diseases | disease perturbations changing expression of CYP4F2 gene from the GEO Signatures of Differentially Expressed Genes for Diseases dataset. | |
| GEO Signatures of Differentially Expressed Genes for Gene Perturbations | gene perturbations changing expression of CYP4F2 gene from the GEO Signatures of Differentially Expressed Genes for Gene Perturbations dataset. | |
| GEO Signatures of Differentially Expressed Genes for Kinase Perturbations | kinase perturbations changing expression of CYP4F2 gene from the GEO Signatures of Differentially Expressed Genes for Kinase Perturbations dataset. | |
| GEO Signatures of Differentially Expressed Genes for Small Molecules | small molecule perturbations changing expression of CYP4F2 gene from the GEO Signatures of Differentially Expressed Genes for Small Molecules dataset. | |
| GEO Signatures of Differentially Expressed Genes for Transcription Factor Perturbations | transcription factor perturbations changing expression of CYP4F2 gene from the GEO Signatures of Differentially Expressed Genes for Transcription Factor Perturbations dataset. | |
| GEO Signatures of Differentially Expressed Genes for Viral Infections | virus perturbations changing expression of CYP4F2 gene from the GEO Signatures of Differentially Expressed Genes for Viral Infections dataset. | |
| GO Biological Process Annotations 2015 | biological processes involving CYP4F2 gene from the curated GO Biological Process Annotations 2015 dataset. | |
| GO Biological Process Annotations 2023 | biological processes involving CYP4F2 gene from the curated GO Biological Process Annotations 2023 dataset. | |
| GO Biological Process Annotations 2025 | biological processes involving CYP4F2 gene from the curated GO Biological Process Annotations2025 dataset. | |
| GO Cellular Component Annotations 2015 | cellular components containing CYP4F2 protein from the curated GO Cellular Component Annotations 2015 dataset. | |
| GO Cellular Component Annotations 2023 | cellular components containing CYP4F2 protein from the curated GO Cellular Component Annotations 2023 dataset. | |
| GO Cellular Component Annotations 2025 | cellular components containing CYP4F2 protein from the curated GO Cellular Component Annotations 2025 dataset. | |
| GO Molecular Function Annotations 2015 | molecular functions performed by CYP4F2 gene from the curated GO Molecular Function Annotations 2015 dataset. | |
| GO Molecular Function Annotations 2023 | molecular functions performed by CYP4F2 gene from the curated GO Molecular Function Annotations 2023 dataset. | |
| GO Molecular Function Annotations 2025 | molecular functions performed by CYP4F2 gene from the curated GO Molecular Function Annotations 2025 dataset. | |
| GTEx eQTL 2025 | SNPs regulating expression of CYP4F2 gene from the GTEx eQTL 2025 dataset. | |
| GTEx Tissue Gene Expression Profiles | tissues with high or low expression of CYP4F2 gene relative to other tissues from the GTEx Tissue Gene Expression Profiles dataset. | |
| GTEx Tissue Gene Expression Profiles 2023 | tissues with high or low expression of CYP4F2 gene relative to other tissues from the GTEx Tissue Gene Expression Profiles 2023 dataset. | |
| GTEx Tissue Sample Gene Expression Profiles | tissue samples with high or low expression of CYP4F2 gene relative to other tissue samples from the GTEx Tissue Sample Gene Expression Profiles dataset. | |
| GWAS Catalog SNP-Phenotype Associations | phenotypes associated with CYP4F2 gene in GWAS datasets from the GWAS Catalog SNP-Phenotype Associations dataset. | |
| GWAS Catalog SNP-Phenotype Associations 2025 | phenotypes associated with CYP4F2 gene in GWAS datasets from the GWAS Catalog SNP-Phenotype Associations 2025 dataset. | |
| GWASdb SNP-Disease Associations | diseases associated with CYP4F2 gene in GWAS and other genetic association datasets from the GWASdb SNP-Disease Associations dataset. | |
| GWASdb SNP-Phenotype Associations | phenotypes associated with CYP4F2 gene in GWAS datasets from the GWASdb SNP-Phenotype Associations dataset. | |
| Heiser et al., PNAS, 2011 Cell Line Gene Expression Profiles | cell lines with high or low expression of CYP4F2 gene relative to other cell lines from the Heiser et al., PNAS, 2011 Cell Line Gene Expression Profiles dataset. | |
| HMDB Metabolites of Enzymes | interacting metabolites for CYP4F2 protein from the curated HMDB Metabolites of Enzymes dataset. | |
| HPA Cell Line Gene Expression Profiles | cell lines with high or low expression of CYP4F2 gene relative to other cell lines from the HPA Cell Line Gene Expression Profiles dataset. | |
| HPA Tissue Gene Expression Profiles | tissues with high or low expression of CYP4F2 gene relative to other tissues from the HPA Tissue Gene Expression Profiles dataset. | |
| HPA Tissue Protein Expression Profiles | tissues with high or low expression of CYP4F2 protein relative to other tissues from the HPA Tissue Protein Expression Profiles dataset. | |
| HPA Tissue Sample Gene Expression Profiles | tissue samples with high or low expression of CYP4F2 gene relative to other tissue samples from the HPA Tissue Sample Gene Expression Profiles dataset. | |
| Hub Proteins Protein-Protein Interactions | interacting hub proteins for CYP4F2 from the curated Hub Proteins Protein-Protein Interactions dataset. | |
| HuGE Navigator Gene-Phenotype Associations | phenotypes associated with CYP4F2 gene by text-mining GWAS publications from the HuGE Navigator Gene-Phenotype Associations dataset. | |
| HumanCyc Pathways | pathways involving CYP4F2 protein from the HumanCyc Pathways dataset. | |
| InterPro Predicted Protein Domain Annotations | protein domains predicted for CYP4F2 protein from the InterPro Predicted Protein Domain Annotations dataset. | |
| JASPAR Predicted Human Transcription Factor Targets 2025 | transcription factors regulating expression of CYP4F2 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Human Transcription Factor Targets dataset. | |
| JASPAR Predicted Mouse Transcription Factor Targets 2025 | transcription factors regulating expression of CYP4F2 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Mouse Transcription Factor Targets 2025 dataset. | |
| JASPAR Predicted Transcription Factor Targets | transcription factors regulating expression of CYP4F2 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Transcription Factor Targets dataset. | |
| KEGG Pathways | pathways involving CYP4F2 protein from the KEGG Pathways dataset. | |
| KEGG Pathways 2026 | pathways involving CYP4F2 protein from the KEGG Pathways 2026 dataset. | |
| Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles | cell lines with high or low copy number of CYP4F2 gene relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles dataset. | |
| KnockTF Gene Expression Profiles with Transcription Factor Perturbations | transcription factor perturbations changing expression of CYP4F2 gene from the KnockTF Gene Expression Profiles with Transcription Factor Perturbations dataset. | |
| LINCS L1000 CMAP Chemical Perturbation Consensus Signatures | small molecule perturbations changing expression of CYP4F2 gene from the LINCS L1000 CMAP Chemical Perturbations Consensus Signatures dataset. | |
| LINCS L1000 CMAP CRISPR Knockout Consensus Signatures | gene perturbations changing expression of CYP4F2 gene from the LINCS L1000 CMAP CRISPR Knockout Consensus Signatures dataset. | |
| LOCATE Predicted Protein Localization Annotations | cellular components predicted to contain CYP4F2 protein from the LOCATE Predicted Protein Localization Annotations dataset. | |
| MotifMap Predicted Transcription Factor Targets | transcription factors regulating expression of CYP4F2 gene predicted using known transcription factor binding site motifs from the MotifMap Predicted Transcription Factor Targets dataset. | |
| MSigDB Cancer Gene Co-expression Modules | co-expressed genes for CYP4F2 from the MSigDB Cancer Gene Co-expression Modules dataset. | |
| MSigDB Signatures of Differentially Expressed Genes for Cancer Gene Perturbations | gene perturbations changing expression of CYP4F2 gene from the MSigDB Signatures of Differentially Expressed Genes for Cancer Gene Perturbations dataset. | |
| MW Enzyme Metabolite Associations | interacting metabolites for CYP4F2 protein from the MW Gene Metabolite Associations dataset. | |
| NIBR DRUG-seq U2OS MoA Box Gene Expression Profiles | drug perturbations changing expression of CYP4F2 gene from the NIBR DRUG-seq U2OS MoA Box dataset. | |
| Pathway Commons Protein-Protein Interactions | interacting proteins for CYP4F2 from the Pathway Commons Protein-Protein Interactions dataset. | |
| PerturbAtlas Signatures of Differentially Expressed Genes for Gene Perturbations | gene perturbations changing expression of CYP4F2 gene from the PerturbAtlas Signatures of Differentially Expressed Genes for Gene Perturbations dataset. | |
| PFOCR Pathway Figure Associations 2023 | pathways involving CYP4F2 protein from the PFOCR Pathway Figure Associations 2023 dataset. | |
| PFOCR Pathway Figure Associations 2024 | pathways involving CYP4F2 protein from the Wikipathways PFOCR 2024 dataset. | |
| Reactome Pathways 2014 | pathways involving CYP4F2 protein from the Reactome Pathways dataset. | |
| Reactome Pathways 2024 | pathways involving CYP4F2 protein from the Reactome Pathways 2024 dataset. | |
| Roadmap Epigenomics Cell and Tissue DNA Methylation Profiles | cell types and tissues with high or low DNA methylation of CYP4F2 gene relative to other cell types and tissues from the Roadmap Epigenomics Cell and Tissue DNA Methylation Profiles dataset. | |
| Roadmap Epigenomics Histone Modification Site Profiles | histone modification site profiles with high histone modification abundance at CYP4F2 gene from the Roadmap Epigenomics Histone Modification Site Profiles dataset. | |
| RummaGEO Drug Perturbation Signatures | drug perturbations changing expression of CYP4F2 gene from the RummaGEO Drug Perturbation Signatures dataset. | |
| RummaGEO Gene Perturbation Signatures | gene perturbations changing expression of CYP4F2 gene from the RummaGEO Gene Perturbation Signatures dataset. | |
| Sci-Plex Drug Perturbation Signatures | drug perturbations changing expression of CYP4F2 gene from the Sci-Plex Drug Perturbation Signatures dataset. | |
| TargetScan Predicted Nonconserved microRNA Targets | microRNAs regulating expression of CYP4F2 gene predicted using nonconserved miRNA seed sequences from the TargetScan Predicted Nonconserved microRNA Targets dataset. | |
| TCGA Signatures of Differentially Expressed Genes for Tumors | tissue samples with high or low expression of CYP4F2 gene relative to other tissue samples from the TCGA Signatures of Differentially Expressed Genes for Tumors dataset. | |
| TISSUES Curated Tissue Protein Expression Evidence Scores | tissues with high expression of CYP4F2 protein from the TISSUES Curated Tissue Protein Expression Evidence Scores dataset. | |
| TISSUES Curated Tissue Protein Expression Evidence Scores 2025 | tissues with high expression of CYP4F2 protein from the TISSUES Curated Tissue Protein Expression Evidence Scores 2025 dataset. | |
| TISSUES Experimental Tissue Protein Expression Evidence Scores | tissues with high expression of CYP4F2 protein in proteomics datasets from the TISSUES Experimental Tissue Protein Expression Evidence Scores dataset. | |
| TISSUES Text-mining Tissue Protein Expression Evidence Scores | tissues co-occuring with CYP4F2 protein in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores dataset. | |
| TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025 | tissues co-occuring with CYP4F2 protein in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025 dataset. | |
| WikiPathways Pathways 2014 | pathways involving CYP4F2 protein from the Wikipathways Pathways 2014 dataset. | |
| WikiPathways Pathways 2024 | pathways involving CYP4F2 protein from the WikiPathways Pathways 2024 dataset. | |
